IN THE SPOTLIGHT

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC

Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients

Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients

FDA Accepts NDA for Zidesamtinib in Previously Treated ROS1+ NSCLC

FDA Accepts NDA for Zidesamtinib in Previously Treated ROS1+ NSCLC

FDA Accepts NDA for Zidesamtinib in Advanced ROS1+ NSCLC

FDA Accepts NDA for Zidesamtinib in Advanced ROS1+ NSCLC

FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC

FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC

Bayer Receives FDA Accelerated Approval for HER2-Targeting Kinase Inhibitor in NSCLC

Bayer Receives FDA Accelerated Approval for HER2-Targeting Kinase Inhibitor in NSCLC

KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis

KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis

First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs

First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs

Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort

Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort

Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis

Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis